FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximabWU ZHANG; GORDON, Michael; IQBAL, Syma et al.Journal of clinical oncology. 2007, Vol 25, Num 24, pp 3712-3718, issn 0732-183X, 7 p.Article

A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601)KOIZUMI, Wasaburo; NAKAYAMA, Norisuke; NAKATANI, Kento et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 2, pp 407-413, issn 0344-5704, 7 p.Article

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)HIGUCHI, Katsuhiko; TANABE, Satoshi; SAKUYAMA, Toshikazu et al.European journal of cancer (1990). 2014, Vol 50, Num 8, pp 1437-1445, issn 0959-8049, 9 p.Article

Risk of Superficial Squamous Cell Carcinoma Developing in the Head and Neck Region in Patients With Esophageal Squamous Cell CarcinomaKATADA, Chikatoshi; MUTO, Manabu; NEMOTO, Masayuki et al.The Laryngoscope. 2012, Vol 122, Num 6, pp 1291-1296, issn 0023-852X, 6 p.Article

Optimal dose-finding study of Bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancerKOIZUMI, Wasaburo; TANABE, Satoshi; HIGUCHI, Katsuhiko et al.Anticancer research. 2006, Vol 26, Num 5B, pp 3797-3802, issn 0250-7005, 6 p.Article